Novavax (NVAX) to Release Quarterly Earnings on Thursday

Novavax (NASDAQ:NVAX) is anticipated to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $90.2580 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Novavax Trading Up 1.1%

Shares of NASDAQ NVAX opened at $9.46 on Wednesday. The company has a market cap of $1.54 billion, a PE ratio of 5.28 and a beta of 2.58. The company has a debt-to-equity ratio of 5.93, a quick ratio of 2.24 and a current ratio of 2.27. The firm’s 50 day moving average price is $8.12 and its 200-day moving average price is $7.99. Novavax has a 52-week low of $5.01 and a 52-week high of $10.64.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quarry LP purchased a new stake in shares of Novavax during the third quarter valued at $33,000. Danske Bank A S acquired a new position in shares of Novavax during the 3rd quarter worth approximately $64,000. State of Wyoming purchased a new position in Novavax during the second quarter worth about $52,000. Scientech Research LLC acquired a new stake in shares of Novavax during the 3rd quarter worth about $96,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Novavax in the fourth quarter valued at $75,000. Institutional investors own 53.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. B. Riley Financial reiterated a “buy” rating and issued a $16.00 price target (down from $18.00) on shares of Novavax in a report on Monday, November 10th. Wall Street Zen cut Novavax from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. TD Cowen decreased their target price on Novavax from $8.00 to $7.00 and set a “hold” rating on the stock in a research report on Tuesday, November 4th. BTIG Research restated a “buy” rating and set a $19.00 price target on shares of Novavax in a report on Tuesday, January 20th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novavax in a research note on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, Novavax presently has an average rating of “Hold” and an average target price of $11.25.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.